<p><strong> </strong><strong>When treating a subgroup of high-risk localized patients (≥ 2 of the following: PSA ≥ 40 ng/dL, ≥ Gleason 8, ≥ cT3) </strong><strong>or locally advanced prostate cancer (cN1) with radiation therapy, clinicians should combine ADT with abiraterone acetate and prednisone for 24 months. <em>(Strong Recommendation; Evidence Level: Grade B)</em></strong></p>
Discussion
Discussion
<p>A meta-analysis of phase 3 STAMPEDE trials included patients with high-risk prostate cancer (having ≥ 2 of the following: PSA ≥ 40 ng/dL, ≥ Gleason 8, ≥ cT3) or clinical evidence of pelvic lymph node involvement. In this investigation, patients treated with ADT plus abiraterone acetate 1000 mg PO daily with prednisolone 5 mg PO daily for 24 months in combination with definitive radiation treatment had improved MFS and OS when compared with patients receiving ADT for 24 months with definitive radiation alone.<sup>154</sup></p>